Keywords: bioxell, six-month, loss, improves, italian, biopharmaceutical, firm
BioXell's six-month loss improves 8%
Article | 24 September 2007
Italian biopharmaceutical firm BioXell SpA says that its 6.4 million-euro ($8.9 million) loss for the half-year ended June 30, 2007, represents an 8% improvement on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
